All In Biotech

Drug Trial Radar · NCT02232893

Effect of TU-100 in Patients Undergoing Laparoscopic Colectomy

A Randomized, Double-Blinded, Placebo-Controlled Trial of TU-100 in Patients Undergoing Laparoscopic Colectomy

Last checked: Nov 19, 2026Latest source record: Jun 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

69

Actual

Start

Sep 2014

Primary completion

May 2017

Study completion May 2017

Sponsor

Lead sponsor
Tsumura USAIndustry
Sponsor type
Industry
Collaborators
Cato Research
First posted
Sep 5, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TU-100 is a gastrointestinal drug produced from the three botanical raw materials, Asian ginseng, Zanthoxylum fruit (Japanese pepper), and ginger, based on proprietary aqueous decoction and granulation technology. The aim of this study is to assess the effect of TU-100 on post-operative quality of life during the 4 week postoperative period after straight, hand-assisted, or robot-assisted laparoscopic colectomy. Optimal efficacy parameters for subsequent outcome studies also will be explored.

Conditions

  • Postoperative Ileus

Interventions

  • Daikenchuto (TU-100)Drug

    Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.

  • PlaceboDrug

    Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Quality of Life After Surgery Based on Gastrointestinal Quality of Life Index (GIQLI) Global Score From Baseline to Visit 4.Time frame: Baseline and 15 days

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Los Angeles Site

    Los Angeles, California

  • Aurora Site

    Aurora, Colorado

  • Weston Site

    Weston, Florida

  • Atlanta Site

    Atlanta, Georgia

  • Chicago Site

    Chicago, Illinois

  • Metairie Site

    Metairie, Louisiana

  • Burlington, MA Site

    Burlington, Massachusetts

  • Coon Rapids Site

    Coon Rapids, Minnesota

  • Minneapolis Site

    Minneapolis, Minnesota

  • Jackson Site

    Jackson, Mississippi

  • Cleveland Site

    Cleveland, Ohio

  • Burlington, VT Site

    Burlington, Vermont

  • Spokane Site

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.